ライフサイエンスコーパス: restenotic lesion

1 group included 68 patients with 74 in-stent restenotic lesions.

2 ographic restenosis after gamma radiation of restenotic lesions.

3 nd myocardial infarctions than nonaggressive restenotic lesions.

4 mal formation in atherosclerotic plaques and restenotic lesions.

5 e-tissue-containing myxoid region typical of restenotic lesions.

6 en more striking in (nonstented and stented) restenotic lesions.

7 expression of these factors in VSMCs within restenotic lesions.

8 is increased and MMP-1 is decreased in early restenotic lesions.

9 atheromatous plaques and the development of restenotic lesions.

10 he femoral-popliteal segment in de- novo and restenotic lesions.

11 rominent component in stented and nonstented restenotic lesions.

12 ectable with immunohistochemistry in 4 of 13 restenotic lesions (31%) and in 3 of 37 de novo lesions

13 The majority (55%) of the restenotic lesions after IRT failure were focal (< or =1

14 ative angiographic location of the recurrent restenotic lesion, after treatment of in-stent restenosi

15 days of stenting, ostial lesion, stent for a restenotic lesion and diffuse type ISR.

16 lasty such as renal aorto-ostial lesions and restenotic lesions, as well as after a suboptimal balloo

17 oronary artery lesions (HR 1.46, p < 0.001), restenotic lesions at baseline (HR 1.58, p = 0.006), and

18 ressed by neointimal VSMCs of human coronary restenotic lesions, but not in healthy vessels.

19 that cytomegalovirus (CMV) DNA is present in restenotic lesions from atherectomy specimens.

20 lagen-rich sclerotic content is increased in restenotic lesions from patients with DM.

21 Late restenotic lesions (> 4 years) resembled atheroma and ex

22 atients undergoing optimal DCA of de novo or restenotic lesions in 3.0- to 4.5-mm native coronary art

23 novo atherosclerotic or post-endarterectomy restenotic lesions in native carotid arteries were enrol

24 was safe in select patients with de novo or restenotic lesions in native coronary arteries.

25 Patients with new or restenotic lesions in native upper-extremity arterioveno

26 hese results suggest that the development of restenotic lesions involves localized deposits of specif

27 ar de novo atherosclerotic and, potentially, restenotic lesions) is fueled by more effective second-g

28 ultivessel disease, treatment of an in-stent restenotic lesion), laboratory findings (low baseline he

29 Off-label use was defined as use in restenotic lesions, lesions in a bypass graft, left main

30 Early restenotic lesions (< 1.5 years) contained abundant type

31 bute to the progression and development of a restenotic lesion, many signaling through a common pathw

32 Diminished TF expression in restenotic lesions may in part account for the lower com

33 to stain atherectomy specimens from 29 human restenotic lesions (mean restenosis interval, 6.0+/-4.4

34 Univariate predictors were restenotic lesion (odds ratio [OR]: 2.47, confidence int

35 ergoing percutaneous treatment of de novo or restenotic lesions of the superficial femoral or proxima

36 larly, final IVUS lumen CSA (p = 0.0001) and restenotic lesions (p = 0.006) were found to predict TLR

37 ravascular ultrasound (IVUS) (p = 0.001) and restenotic lesions (p = 0.01).

38 t multivariate predictors for late MACE were restenotic lesion (relative risk [RR] 1.33, p = 0.02), P

39 PIs were repeated in restenotic lesions until sustained success was obtained.

40 DNA from human atherosclerotic and restenotic lesions was used to test the hypothesis that

41 Results in restenotic lesions were similar.

42 Treatment of bare-metal in-stent restenotic lesions with paclitaxel-eluting stents rather